



COMPANY

Agilvax is an immunotherapy company utilizing its proprietary virus-like particle (VLP) platform technology to enable the body's immune system to fight disease. Our lead indications are focused on women's health and infectious diseases impacting global populations, with broad applicability across therapeutic areas.

Lead Program AX09: Targeting Triple-Negative Breast Cancer

Agilvax's lead program AX09, is first being tested a potential therapeutic for triple-negative breast cancer (TNBC). TNBC is the most aggressive form of breast cancer with few treatment options, higher rates of recurrence and overall poorer outcomes. With over 300,000 new cases of TNBC every year globally, there is a critical need for an effective targeted therapy.

Successful eradication of breast cancer stem cells is paramount for effective cancer treatment. AX09 is composed of a VLP that displays a specific portion of a protein, xCT, that is overexpressed in breast cancer stem cells and contributes to chemotherapeutic drug resistance and metastasis. AX09 has been shown to reduce distal metastases in models relevant to human tumor cells.

HIGHLIGHTS

Financing

- Series A complete \$5M
- Non-Dilutive Funding (NIH, SBIR)
- Raising Series B: \$15 million to complete preclinical efficacy and advance to a Phase I clinical trial

Collaborations

- Partnership with Leidos, Inc (malaria vaccine, \$400,000)
- Partnership with HumabsBiomed (RSV vaccine)
- Partnership with Integrated BioTherapeutics (Ebola vaccine)

Intellectual Property

- **Agilvax** has filed a comprehensive patent covering **AX09** (composition of matter and method of use)
- **Agilvax** is the worldwide exclusive license holder to the core VLP technology from the University of New Mexico

PIPELINE

Therapeutic Area	Discovery	Preclinical	Pre-IND	IND
Oncology AAX09	[Progress bar: Discovery, Preclinical, Pre-IND, IND]			
Infectious Disease AX03 HPV	[Progress bar: Discovery, Preclinical, Pre-IND, IND]			
AX05 Malaria	[Progress bar: Discovery, Preclinical, Pre-IND, IND]			
AX14 RSV	[Progress bar: Discovery, Preclinical, Pre-IND, IND] SBIR			

About the Platform

Agilvax's proprietary VLP platform technology stimulates robust and specific immune responses to self and foreign antigens. The platform enables development of products through a unique affinity selection process, where candidates will stimulate an immune response that mimics the selecting antibody. Secondly, the platform allows for the rational engineer and display of specific previously identified epitopes in a highly immunogenic form

TEAM

Federica Pericle, PhD, MBA
President and CEO
Les Stewart
Michael Perrine, MS, MBA
Jayne Christen, PhD
Jerri Caldeira

BOARD

Waneta Tuttle, PhD, MBA – Chairman
CEO Southwest Medical Ventures
Federica Pericle, PhD, MBA
President and CEO
Brad H. Vale, PhD, DVA
CEO of Calaveras Creek Capital and former Head of Johnson and Johnson Development Corporation
Faith L. Charles, JD
Partner in Thompson Hine's Corp. Transactions & Securities
Brian Birk
Managing Partner of Sun Mountain Capital
Ebetuel (Beto) Pallares, PhD
Joseph Advisory Services/Hunt Holdings
Stuart Rose, PhD Founder
of The Bioscience Center and FatPipeBQ

ADVISORY TEAM

George Peoples, MD,
Cancer Insight, former Chief Surgeon at Brooke Army Medical Center
Frank Borriello, MD, PhD
Baxter, Shire, Takeda, Millenium
Enrico Braglia
OneLife, Helsinn
Federica Cavallo, PhD
Associate Professor, University of Turin
Bryce Chackerian, PhD
Associate Professor, University of New Mexico
Naoto Ueno, MD, PhD
MD Anderson Cancer Center
Jack Geltosky, PhD
Pharmaceutical Executive